吉西他滨联合长春瑞滨治疗晚期非小细胞肺癌  

Gemcitabine Combined with Navelbine in treatment of advanced Non-small Cell Lung Cancer

作　　者：杨锡贵[1] 贾丽雅[1] 步兵[1] 刘志方[1] 田禾[1] 周登峰[1] 张锡芹[1] 

机构地区：[1]山东省肿瘤医院

出　　处：《临床肿瘤学杂志》2005年第2期135-136,139,共3页Chinese Clinical Oncology

摘　　要：目的:观察和评价吉西他滨(GEM)联合长春瑞滨(NVB)治疗晚期非小细胞肺癌(NSCLC)的疗效和毒性.方法:GEM 1 000 mg/m2加生理盐水(NS)100 ml,30分钟内滴注,第1、8天;NVB 25 mg/m2加NS 70 ml快速静脉推注,第1、8天.21天为1个周期,至少治疗2个周期. 结果:21例NSCLC患者,10例完成2个周期,6例3个周期,5例4个周期,共治疗58个周期.CR 1例,PR 9例,SD 9例,PD 2例,总有效率(CR+PR)为47.6%;初治8例,复治13例,有效率分别为62.5%(5/8例)和38.5%(5/13例)(P＜0.05);鳞癌8例,腺癌13例,有效率分别为62.5%(5/8例)和38.5%(5/13例)(P＜0.05).中位生存期(MST)11.5个月,1年生存率为42.0%.毒性反应主要有白细胞减少、血小板下降、血红蛋白降低;白细胞减少Ⅲ～Ⅳ度者占28.6%(6/21),血小板下降和血红蛋白下降Ⅲ～Ⅳ度分别为14.3%(3/21)和4.8%(1/21).结论:吉西他滨联合长春瑞滨治疗晚期非小细胞肺癌具有较好的疗效,毒性反应可以耐受,特别是老年患者化疗更适宜.Objective：To evaluate clinical efficacy and toxicity of gemcitabine （GEM） combined with navelbine （NVB） for stage IV non-small cell lung cancer （NSCLC）. Methods：Twenty-one cases with stage IV NSCLC were treated with GEM 1 000 mg/m^2 and NVB 25 mg/m^2 every 21 days for at least 2 cycles. Results：The response rate （RR） was 47.6% （ CR = 1, PR =9 ）. The therapeutic effect was better in the patients initially diagnozed than in the patients in recurrence （ RR ：62.5% VS 38.5% , P 〈 0.05 ）. The therapeutic effect in the patients with squamous cell carcinoma was better than in the patients with adenocarcinoma （RR：62.5% VS 38.5% , P 〈 0.05）. The major foxicities included leukopenia reciuced and hemoglobin redused. The median survival time was 11.5 months and the 1-year survival rate was 42.0% （95% CI 24% - 59% ）. Conclusion：A high response rate was obtained in stage IV NSCLC treated by GEM plus NVB with tolerable toxicity.

关 键 词：非小细胞肺癌 吉西他滨 长春瑞滨 化学治疗 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]